Over the last few years it has been well documented that expiring patents and declining in-house R&D productivity have left many pharmaceutical companies with an urgent need to look outside their organizations to form partnerships to achieve sustainable drug pipeline growth.
Why do they need to look externally? The answer is that their current drug discovery model is capital-intensive, inefficient and unsustainable.
The conventional drug discovery process typically starts with an evaluation of many thousands of compounds. This process can last as long as five years and cost more than $200 Million – and if successful, a drug candidate then enters the long and even more expensive process of clinical trials in hopes of an eventual FDA approval. Clearly, there is a need for a more effective way of discovering, optimizing and selecting new lead drug candidates.
Pharmaceutical companies looking to reduce their internal R&D spending bodes well for companies like ours. Through collaboration and leveraging our proprietary, artificial intelligence-based drug discovery technology platform, CHEMSAS®, we can reduce the time and cost of drug discovery while improving the probability of clinical & commercial success.
By in-licensing our novel, optimized lead compounds, our partners can augment their pipelines in a highly targeted fashion, potentially extend patent life by several years and reduce the immense cost of their traditional drug discovery process by upwards of tens of millions of dollars per successful drug.
In pharmaceutical drug development, speed is only useful if it comes with accuracy – CHEMSAS® delivers both.